𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Adenine arabinoside 5′-monophosphate treatment of chronic type B hepatitis

✍ Scribed by Jay H. Hoofnagle; Gerald Y. Minuk; Geoffrey M. Dusheiko; Daniel F. Schafer; Rodney Johnson; Stephen Straus; E. Anthony Jones; John L. Gerin; Kamal Ishak

Publisher
John Wiley and Sons
Year
1982
Tongue
English
Weight
489 KB
Volume
2
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis

Six patients with chronic type B hepatitis were treated with adenine arabinoside 5'-monophosphate at a dosage of 10 to 15 mg per kg per day for 10 days. All demonstrated an immediate and marked decrease in serum hepatitis B virus DNA and DNA polymerase, and 5 of the 6 became negative for both markers by the end of the period of therapy. One patient remained negative for hepatitis B virus DNA and DNA polymerase when therapy was discontinued. This patient subsequently exhibited clinical, serum biochemical, and histological remission in disease activity concurrent with seroconversion from hepatitis B e antigen to antibody. In the remaining five patients, serum hepatitis B virus DNA and DNA polymerase returned to pretreatment values soon after therapy was stopped, and these patients demonstrated no significant changes in clinical, biochemical, serological, or histological features of the disease. Side effects of the therapy were mild and transient. These results suggest that a 10-day course of adenine arabinoside 5'-monophosphate is not adequate to induce permanent amelioration of infection and disease activity in the majority of patients with chronic type B hepatitis.

📜 SIMILAR VOLUMES

Interferon vs. adenine arabinoside 5′-mo
Interferon vs. adenine arabinoside 5′-monophosphate in patients with anti-HBe-positive chronic hepatitis
✍ Buti, Maria; Jardi, Rosendo; Rodriguez-Frias, Francisco; Allende, Helena; Cotrin 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 393 KB 👁 1 views

Anti-HBe-positive patients with precore mutants may have severe, progressive liver disease. Therapy with interferon has been effective, but relapses are frequent. To evaluate and compare two antiviral treatments, lymphoblastoid interferon fly-IFN) and adenine arabinoside 5'-monophosphate (ARA-AMP),

Randomized controlled trial of adenine a
Randomized controlled trial of adenine arabinoside 5′-monophosphate in chronic active hepatitis B: Comparison of the efficacy in heterosexual and homosexual patients
✍ Patrick Marcellin; Denis Ouzan; Françoise Degos; Christian Brechot; Etienne-Henr 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 459 KB 👁 1 views

Twenty-two heterosexuals and 2 1 homosexuals with chronic active hepatitis B and who had HBsAg, HBeAg and hepatitis B virus DNA in serum were randomized separately to receive adenine arabinoside monophosphate or placebo. In the 10 heterosexuals and nine homosexuals who received placebo, no change in

Antiviral treatment of chronic hepatitis
Antiviral treatment of chronic hepatitis B virus infection: Improvement in liver disease with interferon and adenine arabinoside
✍ George H. Scullard; Ljudevit L. Andres; Harry B. Greenberg; Joseph L. Smith; Vin 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 398 KB 👁 1 views

Twelve of 32 patients lost HBeAg and DNA polymerase from their serum after completing antiviral therapy with interferon and/or adenine arabinoside. Three lost serum HBsAg as well. Loss of corresponding viral markers from hepatic tissue was also seen. There was improvement in symptoms, hepatic tests,

Treatment of chronic type B hepatitis wi
Treatment of chronic type B hepatitis with recombinant α-interferon induces autoantibodies not specific for autoimmune chronic hepatitis
✍ Werner-J. Mayet; Georg Hess; Guido Gerken; Siegbert Rossol; Rita Voth; Michael M 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 443 KB 👁 1 views

Recombinant human a-interferon is now under intensive investigation as therapy for chronic Type B hepatitis. Recent reports have suggested that prolonged a- interferon therapy may induce autoimmune reactions. We have evaluated the problem of autoimmunity related to a-interferon therapy by testing fo